Skip to content

Effect of different doses of adenosine Zusanli injection on pain after laparoscopic cholecystectomy

Effect of different doses of adenosine Zusanli injection on pain after laparoscopic cholecystectomy: a single-center, randomized, double-blind controlled study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089016
Enrollment
Unknown
Registered
2024-08-30
Start date
2024-09-04
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laparoscopic cholecystectomy

Interventions

Group A (control group):Injecting 0.9%NaCl injection with 1ml at bilateral Zusanli points
Group B:Injecting adenosine injection with 0.1mg(1ml) at bilateral Zusanli points
Group C:Injecting adenosine injection with 0.2mg(1ml) at bilateral Zusanli points
Group D:Injecting adenosine with 0.4mg(1ml) at bilateral Zusanli points

Sponsors

Shanghai Fourth People's Hospital affiliated to Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. Patients proposed for laparoscopic cholecystectomy; 3. BMI of 18-30 kg/m^2; 4. ASA classification I to III; 5. Signing of informed consent Voluntarily.

Exclusion criteria

Exclusion criteria: 1. Second or third degree atrioventricular block, sick sinus node syndrome (except patients with artificial pacemakers) ; 2. Patients with pulmonary disease with bronchial stenosis or bronchospasm (such as asthma); 3. Patients with hypersensitivity to adenosine; 4. Persons with communication disorders that prevent them from cooperating with the researcher, such as language comprehension disorders, psychiatric disorders; 5. Those who have had a heart attack or cerebral infarction within six months; 6. Pregnant or lactating women; 7. Infection at the acupuncture point injection site; 8. History of analgesic medication for a continuous period of 3 months prior to enrollment; 9. Other conditions that considered inappropriate for inclusion by the investigators.

Design outcomes

Primary

MeasureTime frame
Pain VAS score;

Secondary

MeasureTime frame
Time of first exhaust ;Time of first bowel ;Time of first water intake;Incidence of nausea and vomiting;Blood interleukin-18 concentration at 6h postoperatively;Intraoperative sufentanil and remifentanil dosage;Intraoperative heart rate and mean arterial pressure;Postoperative Pittsburgh Sleep Quality Score ;Complications associated with acupoint injections;Remedial analgesic dosage;Patient Satisfaction Score;

Countries

China

Contacts

Public ContactChen Guozhong

Shanghai Fourth People's Hospital affiliated to Tongji University

cgzssq2000@sina.com+86 139 6078 9827

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026